PRESENTER

DAY

TITLE

Agenda

June 24-27, 2026

Wednesday, June 24

TIME

6:00pm -8:00pm

TITLE

Faculty Dinner

Thursday, June 25 | Day 1 — Obesity

TIME

7:30am-8:30am

TITLE

 Breakfast & Registration

Session 1: Obesity

Moderators: Carel le Roux and Ildiko Lingvay

TIME

8:30am-8:45am

TITLE

Opening Remarks of the SOLAR Conference 

PRESENTER

Mazen Noureddin, MD, MHSc

Mazen Noureddin, MD, MHSc

TIME

8:45am-9:05am


TITLE

State of the Art Lecture: The Evolving Understanding of the Disease of Obesity that is Impacting Clinical Trials

PRESENTER

Carel le Roux MD, PhD

Carel le Roux MD, PhD

TIME

9:05am-9:25am


TITLE

What did we learn with the STEP and SELECT trials with Semaglutide that changed how we want to do clinical trials now?

PRESENTER

Domenica Rubino, MD

Domenica Rubino, MD

TIME

9:25am-9:35am

TITLE

Break

TIME

9:35am-9:55am

TITLE

What did we learn with the SURMOUNT trials with Tirzepatide that changed how we do clinical trials now?

PRESENTER

Layla Abushamat, MD

Layla Abushamat, MD

TIME

9:55am-10:15am

TITLE

What did we learn with the new phase 2 and 3 trials with Multihormone Agonists that changed how we want to do clinical trials now?

PRESENTER

Ildiko Lingvay, MD

Ildiko Lingvay, MD

TIME

10:15am-10:35am

TITLE

CDs Abstract of Choice - 2 Orals @10 mins 

TIME

10:35am-10:55am


TITLE

Panel discussion

PRESENTER

Domenica Rubino, Dimple Desai, Julia Dunn, Isabel Kloer, Layla Abushamat, Lars Hansen, Kristin Fiorino

Domenica Rubino, Dimple Desai, Julia Dunn, Isabel Kloer, Layla Abushamat, Lars Hansen, Kristin Fiorino

TIME

10:55am-11:00am

TITLE

Lunch Pickup Break (Please Return Promptly)

TIME

11:00am-12:00pm

TITLE

Ipsen Pharmaceuticals Product Theater (Lunch) - Cholestatic Liver Diseases: Discover a Treatment Option in PBC & Learn More About PFIC.

Naim Alkhouri, MD, FAASLD, ABOM

Naim Alkhouri, MD, FAASLD, ABOM

Session 2: Cholestatic Liver Disease / Genetic Liver Disease / and Hepatitis B

Moderators: Raj Vuppalanchi and Lily Dara 

TIME

12:00pm-12:20pm

TITLE

PBC Update: Current Status and Future Directions 

PRESENTER

Raj Vuppalanchi, MD

Raj Vuppalanchi, MD

TIME

12:20pm-12:40pm

TITLE

PSC/AIH/Other Autoimmune Liver Diseases: Novel Agents and Promising Trials

PRESENTER

Lily Dara, MD

Lily Dara, MD

TIME

12:40pm-1:00pm

TITLE

Genetic Liver Diseases 1: What's New in A1AT Deficiency, Wilson Disease, and Hemochromatosis

PRESENTER

Kris Kowdley, MD

Kris Kowdley, MD

TIME

1:00pm-1:20pm

TITLE

Genetic Liver Disease 2: Genetic Cholestasis from PFIC to Alagille Syndrome to BASD

PRESENTER

Wing-Kin Syn, MD

Wing-Kin Syn, MD

TIME

1:20pm-1:40pm

TITLE

Panel Discussion 

PRESENTER

Panel: Kris Kowdley, Wing-Kin Syn

Panel: Kris Kowdley, Wing-Kin Syn

TIME

1:40pm-2:00pm

TITLE

Break 

Moderators: Norah Terrault 

TIME

2:00pm-2:20pm

TITLE

Practice Guidelines and Trials Challenges for Chronic HBV and HDV: Are We Moving the Needle?

PRESENTER

Theo Heller, MD

Theo Heller, MD

TIME

2:20pm-2:40pm

TITLE

Update on Clinical Trials of Novel Agents Targeting Functional Cure for HBV

PRESENTER

Norah Terrault, MD

Norah Terrault, MD

TIME

2:40pm-3:00pm

TITLE

CHB Treatment and HCV Elimination in 2030: Can we Predict the Future?

PRESENTER

Nancy Reau, MD

Nancy Reau, MD

TIME

3:00pm-3:20pm

TITLE

Panel Discussion 

PRESENTER

Panel: Theo Heller, Nancy Reau

Panel: Theo Heller, Nancy Reau

TIME

3:20pm -6:00pm

TITLE

Meetings, Poster Viewing, and Self-Directed Learning

TIME

6:00pm-8:00pm

TITLE

Reception

Friday, June 26  | Day 2 — MASH


TIME

8:00am - 9:00am

TITLE

Gilead Product Theater (Breakfast) 

Session 3: Clinical & Research Implications in MASH

Moderators: Naim Alkhouri & Manu Chakavarthy

TIME

9:00am-9:20am

TITLE

The Stephen Harrison State of Art Lecture: MASH in 2026

PRESENTER

Mazen Noureddin, MD, MHSc

Mazen Noureddin, MD, MHSc

TIME

9:20am-9:40am

TITLE

Resmetirom and Semaglutide are now FDA Approved: What Should Clinicians Do Today?

PRESENTER

Naim Alkhouri, MD

Naim Alkhouri, MD

TIME

9:40am-10:00am

TITLE

Current Update on Phase 3 Trials

PRESENTER

Alina Allen, MD

Alina Allen, MD

TIME

10:00am-10:20am

TITLE

Panel Discussion 

Mazen Noureddin, Alina Allen

Mazen Noureddin, Alina Allen

TIME

10:20am-10:35am

TITLE

Break

TIME

10:35am-10:50am

TITLE

RNA Interference and Genetic Therapies

PRESENTER

Naga Chalasani, MD

Naga Chalasani, MD

TIME

10:50am-11:10am

TITLE

PROs in MASH Trials, Which One and How to Implement

PRESENTER

Zobair Younossi, MD

Zobair Younossi, MD

TIME

11:10am -11:30am

TITLE

CDs Abstract of Choice – 2 Orals @10 mins

TIME

11:30am-11:50pm

TITLE

Panel Discussion 

PRESENTER

Panel: Christophe Arbet-Engels, Becky Taub, Zobair Younossi, Mazen Noureddin, Meena Bansal, Naga Chalasani

Panel: Christophe Arbet-Engels, Becky Taub, Zobair Younossi, Mazen Noureddin, Meena Bansal, Naga Chalasani

TIME

11:50am-12:00pm

TITLE

Lunch Pickup Break (Please Return Promptly)

TIME

12:00pm-1:00pm

TITLE

Madrigal Pharmaceuticals Product Theater (Lunch) 

Session 4: NITs and Trials Design

Moderators: Mazen Noureddin & Stuart Kendrick

TIME

1:00pm-1:20pm

TITLE

NITs: The Reasonably Likely to Predict Outcomes and the path to full Validation

PRESENTER

Jörn Schattenberg, MD

Jörn Schattenberg, MD

TIME

1:20pm-1:40pm

TITLE

Update on the Role of liver biopsy in MASH trials: When do I use it?

PRESENTER

Cynthia Behling, MD

Cynthia Behling, MD

TIME

1:40pm-2:00pm

TITLE

Designing Non-Cirrhotic MASH Trials without Liver Biopsy: Pros & Cons

PRESENTER

TIME

2:00pm-2:20pm

TITLE

Designing Cirrhosis Trials

PRESENTER

Arun Sanyal, MD

Arun Sanyal, MD

TIME

2:20pm-2:50pm

TITLE

Updates on Promising NITs (ProC3, cT1, MASEF score)

PRESENTER

Manu Chakravarthy, MD, Carlos Duncker, MD, PhD & Frank Amato

Manu Chakravarthy, MD, Carlos Duncker, MD, PhD & Frank Amato

TIME

2:50pm-3:10pm

TITLE

CDs Abstract of Choice – 2 Orals @10 mins

TIME

3:10pm-3:25pm

TITLE

Panel Discussion 

PRESENTER

Panel: Jörn Schattenberg, Cynthia Behling,  Bilal Hameed, Arun Sanyal

Panel: Jörn Schattenberg, Cynthia Behling,  Bilal Hameed, Arun Sanyal

Saturday, June 27 | Day 3 — MASH, MetALD and ALD

TIME

7:15am-8:15am

TITLE

Breakfast & CME or Product Theater 

Session 5: Dual Perspectives: Sponsors & Site Exchange

Moderators: Ramy Younes & Alina Allen

TIME

8:15am-8:35am

TITLE

Overcoming MASH Trials Difficulties, Liver Biopsy, Biomarkers and Retention

PRESENTER

Rashmee Patil, MD

Rashmee Patil, MD

TIME

8:35am-8:55am

TITLE

Use of GLP-1 and their Effect in MASH Trials: How to control and mitigate during trials

PRESENTER

Meena Bansal, MD

Meena Bansal, MD

TIME

8:55am-9:15am

TITLE

What is a Stellar MASH Site: The Sponsor’s Wish List

PRESENTER

Michelle Long, MD

Michelle Long, MD

TIME

9:15am-9:35am

TITLE

Panel Discussion 

PRESENTER

Panel: Ramy Younes, Meena Bansal, Rashmee Patil, Michelle Long

Panel: Ramy Younes, Meena Bansal, Rashmee Patil, Michelle Long

TIME

9:35am-9:50am

TITLE

Break

Session 6: Shark Tank: Innovative Biotechs meet KOLs and Big Pharma (MASH)

Sharks: Mazen Noureddin, Naim Alkhouri, Bill Sibold, Stuart Kendrick 

TIME

9:50am-10:00am

TITLE

Company 1  (Kriya)

TIME

10:00am-10:10am

TITLE

Sharks

TIME

10:10am-10:20am

TITLE

Company 2 (HepaNova)

TIME

10:20am-10:30am

TITLE

Sharks

TIME

10:30am-10:40am

TITLE

Company 3 (Opko)

TIME

10:40am-10:50am

TITLE

Sharks

TIME

10:50am-11:00am

TITLE

Lunch Pickup Break (Please Return Promptly)

TIME

11:00am-12:00pm

TITLE

Boehringer Ingelheim Pharmaceuticals Product Theater (Lunch)

Session 7: The Future of MetALD and ALD

Moderators: Mazen Noureddin

TIME

12:05pm-12:25pm

TITLE

Current Update on Clinical Trials for MetALD and ALD

PRESENTER

Naim Alkhouri, MD

Naim Alkhouri, MD

TIME

12:25pm-12:45pm

TITLE

MetALD and ALD Phase 2 Trials Design

PRESENTER

Brian Lee, MD

Brian Lee, MD

TIME

12:45pm-1:05pm

TITLE

MetALD and ALD Phase 3 Trials Design

PRESENTER

Mazen Noureddin, MD

Mazen Noureddin, MD

TIME

1:05pm-1:25pm

TITLE

Panel Discussion 

Naim Alkhouri, Brian Lee

Naim Alkhouri, Brian Lee

Session 8: Dual Perspectives: Sponsors & Sites Exchange

Moderators: Lisa Boyette 

TIME

1:25pm-1:45pm

TITLE

How to Deal with Active Alcohol Intake during the trials

PRESENTER

Jessica Mellinger, MD 

Jessica Mellinger, MD 

TIME

1:45pm-2:05pm

TITLE

NIT in MetALD/ALD: The Reasonably Likely to Predict Outcomes

PRESENTER

Ashwani Singal, MD

Ashwani Singal, MD

TIME

2:05pm-2:25pm

TITLE

Sites Challenges in MetALD and ALD trials (Sites vs Sponsors Perspective (10 min each)

PRESENTER

Nikhil Vergis, MD (sponsor) & Bilal Hameed, MD (Site)

Nikhil Vergis, MD (sponsor) & Bilal Hameed, MD (Site)

TIME

2:25pm – 2:35pm

TITLE

CDs Abstract of Choice – 1 Oral @10 mins

TIME

2:35pm-2:55pm

TITLE

Panel Discussion 

PRESENTER

Panel: Ramy Younes, Nikhil Vergis, Manu Chakravarthy, Lisa Boyette

Panel: Ramy Younes, Nikhil Vergis, Manu Chakravarthy, Lisa Boyette

TIME

2:55pm-3:10pm

TITLE

Break

Session 9: Shark Tank: Innovative Biotechs meet KOLs and Big Pharma (ALD/MetALD)

Sharks:  Mazen Noureddin, Nikhil Vergis and Brian Lee 

TIME

3:10pm-3:20pm

TITLE

Company 1 (Gyre)

TIME

3:20pm-3:30pm

TITLE

Sharks

TIME

3:30pm-3:40pm

TITLE

Company 2 (Altimmune)

TIME

3:40pm-3:50pm

TITLE

Sharks

TIME

3:50pm-4:00pm

TITLE

Closing Remarks

PRESENTER

Mazen Noureddin, MD & Naim Alkhouri, MD

Mazen Noureddin, MD & Naim Alkhouri, MD

Connecting liver, obesity, and metabolic science to improve patient care.

This conference looks at the bigger picture—how liver disease, obesity, and metabolic dysfunction intertwine. It creates a space where clinicians, researchers, and industry experts can break silos, share insights, and shape the future of care together. By weaving cutting-edge science with real-world clinical strategies, it challenges participants to rethink how breakthroughs move from the lab to the patient.